A cross-sectional study assessing the relationship between disease and burden associated with ATTR-CM found that both patients ... Federation on Transthyretin Amyloid Cardiomyopathy The World ...

The study investigated the efficacy and safety of acoramidis given twice daily compared with placebo, in subjects with ATTR-CM. The study met its primary clinical endpoints by significantly ...

OXFORD, England, Nov. 20, 2024 /PRNewswire/ -- Ultromics' EchoGo ® Amyloidosis, clinical AI for echocardiography with the potential to revolutionize early detection of Cardiac Amyloidosis ...